# Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

> **NCT01298011** · PHASE2 · COMPLETED · sponsor: **Pancreatic Cancer Research Team** · enrollment: 25 (actual)

## Conditions studied

- Resectable Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine and Abraxane

## Key facts

- **NCT ID:** NCT01298011
- **Lead sponsor:** Pancreatic Cancer Research Team
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-12
- **Final completion:** 2015-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01298011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01298011, "Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01298011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*